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Abstract EMMPRIN (extracellular matrix metalloproteinase
inducer) stimulates fibroblast metalloproteinases (MMP) 1, 2
and 3 (Kataoka et al. (1993) Cancer Res. 53, 3154^3158). Here
we focus on MMP-1, showing that in lung tumors, MMP-1’s
cognate mRNA is strongly expressed in stromal fibroblasts
adjacent to EMMPRIN-expressing tumor cells. In vitro,
EMMPRIN upregulates MMP-1 mRNA expression in a
concentration-dependent manner, with a peak accumulation at
24 h. The response is genistein-sensitive, suggesting it is
dependent on tyrosine kinase activity. Analysis of tyrosine
phosphorylation-dependent MAP kinases ERK 1/2, SAPK/JNK,
and p38 showed that the activity of p38 but not that of the other 2
kinases was elevated in response to EMMPRIN. That p38
activity was required for EMMPRIN stimulation of MMP-1
was evident from results showing that the p38 inhibitor
SB203580 blocked this response. This is the first available
information regarding the mechanism by which tumor-associated
molecules upregulate MMP synthesis in stromal fibroblasts.
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1. Introduction
Tumor growth and metastasis require the breakdown of
extracellular matrix, the components of which may be broken
down collectively by matrix metalloproteinases. The regula-
tion of these enzymes in tumorigenesis is poorly understood
[1^3]. Although both tumor and stromal cells express MMPs
localization studies show that ¢broblasts are the primary
source of MMPs in most tumors [4^8]. Our survey of human
non-small cell lung carcinomas was consistent with this, thus
supporting the notion that tumor-derived factors stimulate
nearby ¢broblasts to synthesize MMPs.
The purpose of the present study was to identify elements
of the signaling pathway mediating extracellular matrix metal-
loproteinase inducer (EMMPRIN) stimulation of ¢broblast
MMP-1. Using chemical inhibitors of key signaling molecules,
we determined that protein tyrosine kinases play an important
role. More speci¢cally, the activity of the p38 MAP kinase
was required for the response. This is the ¢rst information
regarding the mechanism by which tumor cells activate
MMP-1 in adjacent ¢broblasts, and demonstrates that p38
MAP kinase is an important regulator of MMP-1 gene ex-
pression.
2. Materials and methods
2.1. Materials
Samples of non-small cell lung carcinomas were collected at UCSF-
a⁄liated hospitals (Mo⁄tt-Long Hospital, UCSF/Mount Zion Hos-
pital, and the Veterans Administration Hospital). Samples were frozen
with or without ¢xation in 10% formalin. 16-Lu lung ¢broblasts were
purchased from the American Tissue Cell Culture facility (Bethesda,
MD, USA). T7 and SP6 RNA polymerases, salmon sperm DNA,
EcoRI restriction enzyme, random priming kits, and Trizol reagent
were from Gibco. Probes used in Northern blots were produced by
PCR using human cDNA as template. PCR products were cloned into
TA cloning vector (Invitrogen). Acrylamide, Trizma base, boric acid,
NaCl, tRNA, and sodium citrate were from Sigma. Ilford K5D emul-
sion was purchased from Polysciences. Kodak developer and ¢xative
were used for in situ hybridization. Genistein, bisindolylmaleimide,
PD98059, PP-1, KT5720, pertussis toxin, and SB203580 signal trans-
duction inhibitors were from Calbiochem (La Jolla, CA, USA). Anti-
bodies against p42/44, p38, and SAPK/JNK were purchased from
New England Biolabs (Beverly, MA, USA).
2.2. Puri¢cation of EMMPRIN
EMMPRIN was puri¢ed from non-small cell lung carcinoma cell
(either LX-1 or NCI H460) membranes. Homogenates from these cells
were passed over immunoa⁄nity columns made with monoclonal [9]
or polyclonal anti-EMMPRIN antibody (made with A⁄-Gel 10, Bio-
Rad). Rabbit anti-EMMPRIN polyclonal antiserum was generated
against the synthetic peptide NH2-DALPGQKTEEKVDSDDQW-
GC-COOH [10]. The antibody recognized puri¢ed native EMMPRIN
on Western blot (data not shown). For puri¢cation, lung tumor cell
homogenates were loaded onto the column and the column was
washed several times with 0.1 M HEPES bu¡er. EMMPRIN was
eluted with 0.1 N acetic acid and concentrated in Centriprep and
Centricon-10 columns (Amicon; Beverly, MA, USA).
2.3. In situ hybridization
Frozen sections of tumor and normal lung were probed with sense
and antisense 35S-labeled ribonucleoprobes corresponding to EMM-
PRIN, MMP-1 and MMP-2, and in situ hybridization was carried out
as described [11]. Brie£y, 6-Wm thick tissue sections were ¢xed in 4%
paraformaldehyde and treated with proteinase K and acetic anhydride
prior to hybridization. The slides were incubated overnight at 55‡C,
then washed with 0.1USSC at 62‡C for 2 h. After dehydration they
were dipped in emulsion and exposed for 2^3 weeks prior to develop-
ing. EMMPRIN, MMP-1 and MMP-2 were localized with riboprobes
synthesized from nucleotides 73^403, 825^1091, and 1409^1747, re-
spectively, of their cognate cDNAs [10,12,13]. All probes were cloned
into pTA3 cloning vector [11].
2.4. Cell culture and Northern blot
Human lung ¢broblasts (16-Lu and 13-Lu) and human fetal colon
¢broblasts (CCD-18) were grown in Dulbecco’s modi¢ed Eagle’s
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(DME) medium/F12 (50:50) with essential amino acids (Gibco), sup-
plemented with 10% fetal calf serum, 100 U/ml penicillin, and 100 mg/
ml streptomycin. Cells were grown to con£uence in 6-well plates prior
to starvation in serum-free medium. After 30 h the cells were treated
with EMMPRIN or vehicle control. RNA was collected with Trizol
reagent according to the manufacturer’s instructions.
Total RNA (5^10 Wg) was separated on a 1% agarose/formaldehyde
gel and transferred to nylon (GeneScreen) in 10U SSC bu¡er. The
RNA was ¢xed by UV crosslinking (Stratalinker 1800, Stratagene,
Cambridge, MA, USA). The MMP-1 probe was excised from TA
cloning vector with EcoRI and labeled with 32P-dCTP by random
priming. The GAPDH cDNA probe was made as described [11]
and used as an internal control. Hybridization was performed with
ExpressHyb (Clonetics). After 1 h the membranes were washed with
1U SSC at room temperature for 10 min 2U and 1U SSC/1% SDS at
50‡C for 30 min. The membranes were exposed overnight at 380‡C
before developing. Quanti¢cation of data was by densitometry.
2.5. Stimulation of ¢broblasts with puri¢ed EMMPRIN
16-Lu, CCD-18, and 13-Lu ¢broblasts were stimulated with puri¢ed
EMMPRIN (1^3 Wg/ml) for 24 h prior to RNA extraction. In time
course experiments total RNA from 16-Lu cells was extracted after 2,
6, 12, 24, and 48 h. To assess concentration-dependence, one tenth of
the dose (0.3 Wg) used in these experiments was added to 16-Lu ¢bro-
blasts and RNA was collected at 24 h.
2.6. Inhibition of EMMPRIN stimulation by signal transduction
inhibitors
16-Lu ¢broblasts were stimulated with EMMPRIN in the presence
of various signal transduction inhibitors used at saturating concentra-
tion [14^17]. Genistein (67 WM), bisindolylmaleimide I (10 nM),
PD98059 (10^100 WM), PP-1 (30 WM), KT5720 (0.5 WM), pertussis
toxin (100 ng/ml), and SB203580 (1^100 WM) were added to cells in
serum-free medium one hour before and for the duration of EMM-
PRIN exposure. RNA was collected after 12 h and analyzed for the
presence of MMP-1 and GAPDH RNA.
2.7. Immunoblotting analysis of Erk1/2, p38, and SAPK/JNK MAP
kinases
16-Lu ¢broblasts were stimulated with EMMPRIN for 0, 15, 30,
and 60 min prior to harvesting of total cellular protein. For each time
point equal amounts of protein were electrophoresed under reducing
conditions. Identical gels were run simultaneously and the proteins
then transferred to PVDF membrane (Immobilon-P, Millipore, Bed-
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Fig. 1. In situ hybridization of NSCLC, bright¢eld and dark¢eld views. EMMPRIN probe (A, D) is strongly localized to tumor (T), whereas
both MMP-2 (B, E) and MMP-1 (C, F) mRNAs are localized to stromal cells (S) between tumor islands. Magni¢cation 100U.
Fig. 2. In situ hybridization of normal bronchial epithelium, bright¢eld and dark¢eld views. EMMPRIN (A, D) and MMP-1 (C, F) probes re-
veal little to no signal, whereas MMP-2 (B, E) shows low intensity signal in subepithelial ¢broblasts (white arrows in E). S = stroma, L = lumen,
e = epithelium. Magni¢cation 100U.
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ford, MA, USA). After blocking with 5% (w/v) non-fat dry milk, the
blots were incubated for one hour with antibodies directed against
phosphorylated and non-phosphorylated forms of Erk/p44/42,
SAPK/JNK, and p38. Blots were washed 5 min 3U with Tris-bu¡ered
saline/0.1% Tween-20 and incubated with horseradish peroxidase-con-
jugated secondary antibody (1:2000) for one hour. The membranes
were washed as above, and the bands detected by chemiluminescence
after 30 s^1 min exposures.
3. Results
3.1. EMMPRIN mRNA is in tumor cells adjacent to MMP-1
and -2 expressing ¢broblasts
Rapidly frozen NSCLC (6 samples) and normal lung (3
samples) specimens were examined for RNA expression of
EMMPRIN, MMP-1, and MMP-2. In both squamous cell
(n = 4) and adenocarcinoma (n = 2) histologic subtypes, carci-
noma cells uniformly expressed high levels of EMMPRIN
(Fig. 1A and D) and adjacent stromal ¢broblasts strongly
expressed MMP-1 and MMP-2 (Fig. 1B, C, E, F). The latter
is consistent with previous studies reporting elevated metal-
loproteinase expression in lung and head/neck tumors [18^20].
Normal lung samples did not contain detectable levels of
EMMPRIN and MMP-1 mRNAs (Fig. 2A, D, C, F). MMP-2
was weakly expressed in subepithelial ¢broblasts (Fig. 2B and
E).
3.2. EMMPRIN stimulates MMP-1 steady state mRNA in
multiple ¢broblast cell lines
Fibroblast cell lines from both adult lung (16-Lu and 13-
Lu) and fetal colon (CCD-18) showed increased MMP-1
RNA in response to EMMPRIN (Fig. 3), although the degree
of stimulation di¡ered.
3.3. EMMPRIN stimulation of MMP-1 mRNA peaks at 24 h
and is dose dependent
A kinetic analysis of EMMPRIN-induced MMP-1 mRNA
showed a peak intensity of MMP-1 steady state mRNA at 24 h
(Fig. 4A). The response at 24 h was concentration-dependent
(Fig. 4B).
3.4. EMMPRIN activates protein tyrosine kinases
A survey of the e¡ects of various signal transduction inhib-
itors showed a sensitivity of EMMPRIN signaling to the pro-
tein tyrosine kinase inhibitor genistein (Fig. 5). In contrast,
bisindolylmaleimide (PKC inhibitor), PD98059 (MEK1/2 in-
hibitor), KT5720 (PKA inhibitor), PP-1 (Src kinase inhibitor),
and pertussis toxin (G protein inhibitor) did not inhibit the
response. Because protein tyrosine kinases play an important
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Fig. 3. EMMPRIN upregulation of MMP-1 mRNA in three ¢bro-
blast cell lines. With each shown in duplicate, EMMPRIN (EM) or
serum-free medium (SFM) was administered to 16-Lu, CCD-18, and
13-Lu ¢broblasts for 24 h, then total RNA extracted for Northern
blotting. EMMPRIN upregulates steady state MMP-1 mRNA in all
3 cell lines. GAPDH is shown as an internal control.
Fig. 4. Time course and concentration dependence of MMP-1 upre-
gulation. A: EMMPRIN (1^3 Wg/ml) was administered to 16-Lu ¢-
broblasts for 2, 6, 12, 24, or 48 h, then total RNA collected. MMP-
1 steady state mRNA begins to rise at 2 h and peaks at 24 h (B).
EMMPRIN was administered at 3 Wg/ml (undiluted, UDL) or 0.3
Wg/ml (1:10) for 24 h before RNA collection. E¡ect on MMP-1
mRNA is concentration-dependent.
Fig. 5. E¡ect of signal transduction inhibitors on EMMPRIN stim-
ulation of MMP-1. EMMPRIN (3 Wg/ml) was co-administered with
various inhibitors for 10 h prior to total RNA collection. 1: Serum-
free medium; 2: EMMPRIN alone; 3^8: EMMPRIN plus (3) genis-
tein, (4) bisindolylmaleimide, (5) PP-1, (6) PD98059, (7) KT5720,
(8) pertussis toxin. Only genistein shows reduction in MMP-1 steady
state mRNA.
Fig. 6. ERK, SAPK/JNK, and p38 immunoblotting. Total cellular
protein from 16-Lu cells stimulated with EMMPRIN (3 Wg/ml) for
0, 15, 30 and 60 min was analyzed by 10% SDS-PAGE and trans-
ferred to membrane prior to immunoblotting. Reactions with anti-
bodies directed against the non-phosphorylated (A) and phosphory-
lated (B) forms of 3 MAP kinases are shown. Phosphorylation of
p38 at 15 min (lower panel, B) is detected. ERK1/2 (upper panel,
B) and JNK/SAPK (middle panel, B) do not show increased phos-
phorylation. Reactions with antibodies detecting non-phosphorylated
MAP kinases (upper, middle, and lower panels, A) are included as
controls. Biotinylated markers are on the left of each panel.
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role in MAP kinase activation, we investigated the potential
role of MAP kinases.
3.5. EMMPRIN stimulates phosphorylation of p38 but not
other MAP kinases
EMMPRIN stimulated phosphorylation of p38 but not
Erk1/2 or JNK (Fig. 6). Anti-phospho-p38, which detects
dual phosphorylation of p38 at Tyr-182 and Thr-180, showed
enhancement after 15- and 30-min exposure to EMMPRIN,
declining at 60 min (Fig. 6, lower panel). No increased signal
was detected with the phospho-Erk/p44/p42 or phospho-
SAPK/JNK antibodies (Fig. 6, upper and middle panels).
3.6. SB203580 inhibits EMMPRIN upregulation of MMP-1
mRNA
To determine whether the observed stimulation of p38 is
required for EMMPRIN upregulation of MMP-1, we tested
the e¡ect on the response of the p38 inhibitor SB203580.
When SB203580 was co-administered (at saturating doses)
with EMMPRIN, the response decreased by V45% (Fig.
7A and B).
4. Discussion
Our results show that the tumor-associated protein EMM-
PRIN stimulates metalloproteinase-1 mRNA in ¢broblasts via
a p38-dependent signaling pathway. These results are impor-
tant in light of the fact that metalloproteinase activity has
been shown to be necessary for tumor growth [21]. It seems
likely that signaling mechanisms by which tumors increase
local metalloproteinase activity may constitute novel anti-tu-
mor drug targets.
MMP-1 is a member of the matrix metalloproteinase fam-
ily, zinc-dependent metalloenzymes that contribute impor-
tantly to both normal tissue remodeling [22^25] and patho-
logical processes [26^29]. As a type I collagenase, it has the
unique ability to cleave ¢brillar collagen [2]. Although syn-
thesis of metalloproteinases shows a general, albeit di¡eren-
tial, sensitivity to growth factors and cytokines [30,31], and
speci¢c tyrosine kinase- [14], protein kinase C- [14], protein
kinase A- [32], and Src- [33] dependent mechanisms have been
identi¢ed, the control of these enzymes by extracellular stimuli
is largely unknown.
We focused on the control of MMPs by the tumor-associ-
ated protein EMMPRIN. Results of a pharmacological screen
showed that tyrosine kinases, but not PKA, PKC, or Src are
required for EMMPRIN induction of MMP-1. Since tyrosine
kinases are integrally involved in MAP kinase signaling path-
ways, we subsequently examined the e¡ects of inhibitors of
these pathways, speci¢cally the MEK1/2 inhibitor PD98059
and the p38 inhibitor SB203580. The latter signi¢cantly atte-
nuated the response to EMMPRIN, indicating a role for p38
activation in the induction of MMP-1. Consistent with this,
p38 was the only one of three major MAP kinases (ERK1/2,
SAPK/JNK, and p38) that underwent phosphorylation (an
index of activation) in response to EMMPRIN. At saturating
doses of the p38 inhibitor, MMP-1 induction was decreased
by only V45%. Clearly, although p38 plays an important role
in EMMPRIN induction of MMP-1, it does not account en-
tirely for its upregulation. Potential contributors to this in-
duction may include less well-described MAP kinase pathways
[34] or posttranscriptional mechanisms (e.g. prolongation of
RNA half life).
Interestingly, p38 has recently been implicated in the induc-
tion of another metalloproteinase, MMP-9, by phorbol ester
[15]. Originally described by Han et al. [35], p38 is generally
regarded as a stress-activated enzyme and has been shown to
have downstream e¡ects on transcription factor activation
[36], actin ¢lament rearrangement [37], and matrix degrada-
tion ([15] and this report). As such, p38 eventually may be
recognized to play a variety of important roles in the general
process of tissue remodeling.
The identity of signaling molecules linking p38 and MMP-1
transcription remains unknown. Clues are provided, however,
by information regarding known response elements on the
MMP-1 promoter. There is a well-described AP-1 binding
site at 372/367 [38] that is responsive to a variety of stimuli
including phorbol esters, TGF-L, cAMP and TNF-K [39,40].
AP-1 is activated by a variety of signaling cascades, some of
which are p38-dependent [36]. Studies to determine the locus
of the EMMPRIN response element associated with the
MMP-1 gene are in progress.
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Fig. 7. SB203580 inhibits EMMPRIN upregulation of MMP-1. The
speci¢c p38 inhibitor, SB2035580 (10 WM), was preadministered 1 h
and co-administered with EMMPRIN for 10 h prior to total RNA
collection. The graph compares MMP-1/GAPDH signal intensity
and indicates a 45% inhibition by SB203580. SFM = serum-free
medium; EM = EMMPRIN alone; EM/SB = EMMPRIN with
SB203580.
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